• 2 New Drug Evaluations
• New Drug Classification Reports
• Highlights of Safety Related Drug Labeling Changes
• Drug Supply Shortages and Discontinuations
• Approvable/Pending Approvals Drug Report
• CPA Journal Club
• CPA Whitepapers (expert commentary)
• Ask the Informaticist

As a Level 3 subscriber, CPA proprietary Drug and Disease Based Class Reviews are available to you. Additional New Drug Evaluations are available.


Level 2 
Ideal for Physicians Groups, this package gives you access to the following on a monthly basis:

• New Drug Classification Report
• Highlights of Safety Related Drug Labeling Changes
• Drug Supply Shortages and Discontinuations
• Approvable/Pending Approvals Drug Report
• CPA Journal Club
• CPA Whitepapers (expert commentary)
• Ask the Informaticist

As a Level 2 subscriber, CPA proprietary Drug and Disease Based Class Reviews are available to you. Additional New Drug Evaluations are available.


Level 1 
Ideal for Individual Pharmacists, Clinical Pharmacy Departments and Physicians, this package gives you access to the following on a monthly basis:

• New Drug Classification Report
• Highlights of Safety Related Drug Labeling Changes
• Approvable/Pending Approvals Drug Report
• CPA Journal Club
• CPA Whitepapers (expert commentary)
• Ask the Informaticist

As a Level 1 subscriber, CPA proprietary Drug and Disease Based Class Reviews are available to you. Additional New Drug Evaluations are available.


New Drug Classification
The New Drug Classification is a monthly report produced by Clinical Pharmacy Associates that lists new FDA-approved medications including indications, dosage formulations, mechanisms of action, warnings, unusual adverse events, dosage and administration, average wholesale price (AWP) and a list of therapeutic alternatives.

Each report is created by our team of experienced clinical pharmacists using FDA Center for Drug Evaluation and Research (CDER) and other supplemental expert resources. Our professionals review these websites throughout the month to issue monthly reports.

The most up-to-date new drug compilation available, the NDC Report provides information that's critical for pharmacists, P&T Committees, physicians and drug benefit managers. Among its many benefits, it:

• Informs healthcare professionals on the latest in newly approved drugs, indications and formulations
• Assists busy P&T Committees in defining time-lines for formulary review on a monthly basis
• Comes complete with a drug ranking system for timely formulary decisions

Approvable Pending Drugs and Biologics
This report enables health care organizations to meet the financial and clinical pressures associated with the entrance onto the market of new drugs and biologics. Given the fact that these new therapies can represent significant cost, they warrant intense scrutiny and planning. A recent example is the autologous cellular immunotherapy Provenge® (Sipuleucel-T) approved by the FDA in April 2010 for men with advanced prostate cancer. Studies indicate it can prolong life by approximately four months, but at a cost of $93,000 per patient.

The advantage of the Approvable or Pending Approvable Drugs and Biologics report include:

• Support proactive methods for handling specific products prior to FDA approval and market release
• Consideration of the effects of these agents on current formulary products
• Ability to schedule future drug and class reviews for acceptance to formulary
• Anticipate budgetary concerns for expensive agents

New Drug Evaluations (Drug Monographs)
Clinical Pharmacy Associates' Drug Monographs provide the most up-to date clinical information on new drugs approved by the FDA. A useful source of drug information for patient care, they enable clinical decision makers to make better formulary decisions.

To produce the Monographs, our expert clinicians research original clinical articles along with FDA-approved information from pharmaceutical manufacturers. We also provide periodic updates to these reviews. In combination with our New Drug Classification reports, they provide timely drug information accessibility to formulary decision makers and clinicians in hospital, managed care and ambulatory settings.

Drug and Disease-Based Drug Class Reviews
Clinical Pharmacy Associates provides information about drug treatment regardless of therapeutic class for various diseases and conditions. The information is important for:

• Promoting evidence-based medicine
• Formulary decision making
• Treatment protocol development

To generate the information, CPA drug review experts evaluate the clinical literature from a diseases-and-conditions perspective and develop unique comparisons across therapeutic drug classes. Comparative analyses of clinical trials, adverse drug events and clinical efficacy of various therapies are included in the process. Examples include Treatment of Inflammatory Bowel Syndrome, Medications for Bioterrorism and Medications for the Treatment of Depression.

Comparing drug therapies from a disease-based perspective more closely simulates how practitioners treat patients. Our unique approach has proven effective for hospitals, managed care organizations, P&T committees, pharmacy departments, ambulatory care organizations, pharmacies and practitioners.

Highlights of Safety-Related Drug Labeling Changes
Safety-Related Drug Labeling Changes is a monthly report from Clinical Pharmacy Associates that provides a list of drug products with safety labeling changes to any of the following: Boxed Warning, Contraindications, Warnings, Precautions, Adverse Reaction, Patient Package insert/Medication Guide. The report provides critical information to pharmacists, P&T Committees, physicians, nurses and drug benefit managers:
 

• Informs healthcare professionals about the latest updates to a drug's package insert
• Helps P&T Committees make changes to their formulary based on the latest available clinical data
• Serves as a preventive alert mechanism for healthcare professionals providing better awareness regarding patient safety and adverse drug reactions
• Helps healthcare institutions meet Joint Commission standard MM

A team of experienced CPA pharmacists regularly monitors MedWatch Safety Information/Safety Related Drug Labeling Changes and other supplemental expert resources to create the reports. Throughout the month, team members review these websites in order to be able to provide timely updated reports.

Drug Supply Shortages and Discontinuations
Drug supply shortages continue to present a challenge to all healthcare professionals. Interruptions in volume and the type of medications available to patients have increased in recent years. Therefore, greater attention to the subject is now warranted to ensure optimal pharmaceutical care for patients and to maintain patient safety. Supply shortages vary nationwide between regions and between governmental and non-governmental organizations. Click here to see an example of just a few of the drugs in short-supply for 2010. The CPA Analytics subscription can bring you the comprehensive list of Drug Supply Shortages and Discontinuations, an essential tool in your hospital development.